Not Yet Recruiting PHASE1/PHASE2 INTERVENTIONAL 6-arm NCT06132217

A Study of Simmitinib Plus SG001 in Advanced Solid Tumors

A Phase I/II Study To Evaluate The Safety, Tolerability, Pharmacokinetic Profile And Preliminary Efficacy Of Simmitinib Plus SG001 in Patients With Advanced Solid Tumors

Sponsor: Shanghai Runshi Pharmaceutical Technology Co., Ltd

Conditions Advanced Solid Tumor

Interventions SG001 Simmitinib

Updated 3 times since 2023 Last updated: Nov 9, 2023 Started: Jan 30, 2024 Primary completion: Jan 30, 2027 Completion: Jan 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Advanced Solid Tumor, this trial is actively recruiting participants. The trial is conducted by Shanghai Runshi Pharmaceutical Technology Co., Ltd and has accumulated 3 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Dec 2023 — Jul 2024 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Runshi Pharmaceutical Technology Co., Ltd

Data source: Shanghai Runshi Pharmaceutical Technology Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China